CVS Health's adherence to ACA mandates impacts Gilead's drug uptake following FDA approval for Yeztugo.
3 reports, 3 independent
Updated Aug 22
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CVS Health's adherence to ACA mandates impacts Gilead's drug uptake following FDA approval for Yeztugo.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CVS Health's ACA mandates affect uptake of Gilead's newly FDA-approved drug, Yeztugo.1 source
CVS Health declined coverage for Yeztugo drug developed by Gilead Sciences.1 source
Keep exploring
The entities involved
-
CVS Health
company
- FDA
-
Kite
Oglala Lakota performance artist, visual artist, and composer (born 1990)
Nothing else this week.
Related events
- CVS Health, UnitedHealth Group, and Walgreens collectively control over half of U.S. prescription revenue, dominating the market share alongside other large operators.
- ARS Pharmaceuticals Inc. was reported for misleading investors about its coverage progress.
- HSBC restated its 'hold' rating on CVS Health, while Manufacturers Life Insurance Company increased its stake in the company's shares.
- Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
- CVS Health is expanding its drug offerings to include Eli Lilly's Zepbound and Novo Nordisk's Wegovy, while also considering an investment in Roche.
Coverage
Newest first; wire copies grouped- ZacksGILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the for
- StockStoryWhy Gilead Sciences (GILD) Shares Are Sliding Today Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding
- Investing.comGilead stock falls after CVS holds off adding HIV prevention shot to plans Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health